“We are privileged to have such strong industry partners, and we appreciate the industry’s recognition of how collaborating and leveraging community pharmacies can lead to improving the quality of medication use,” said Jeff Newell, chief executive officer of PQS. “We are also excited that our payer partners have acknowledged the unique value community pharmacies provide through higher performance on quality measures and costs avoided due to improved medication use.”
Based upon the latest Impact Assessment from the Centers for Medicare and Medicaid Services (CMS), it has been estimated that from 2011 to 2015 approximately $4.2 billion to $26.9 billion has been saved through avoidable costs among Medicare beneficiaries due to improved medication adherence.
“Over the past few years through the increased adoption of EQuIPP there has been an increased focus on quality and performance information, and we are excited that pharmacies are now able to help strategically position themselves towards one of value and quality,” added Todd Sega, vice president of client relations & services at PQS.
To help continue meeting industry needs and supporting the shift towards value and areas focused on patient outcomes and medication optimization, PQS is dedicated to expanding the number of performance measures hosted in EQuIPP. The additional measures will help to continue serving Medicare beneficiaries along with Medicaid and commercial populations. The measure categories will include the control of Hemoglobin A1c for diabetic populations and expanded measure sets focused on adherence for categories such as asthma inhalers, anti-depressants and antipsychotics.
Since EQuIPP launched in 2013, data for nearly 42 million lives across Medicare, Medicaid and commercial lines of business are now managed within the platform.